Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
145.31
+0.62 (0.43%)
At close: Oct 14, 2025, 4:00 PM EDT
146.00
+0.69 (0.47%)
After-hours: Oct 14, 2025, 7:47 PM EDT
Biogen Stock Forecast
Stock Price Forecast
The 22 analysts that cover Biogen stock have a consensus rating of "Buy" and an average price target of $183.05, which forecasts a 25.97% increase in the stock price over the next year. The lowest target is $115 and the highest is $275.
Price Target: $183.05 (+25.97%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Biogen stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 6 | 6 |
| Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Hold | 15 | 16 | 16 | 16 | 16 | 14 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 27 | 27 | 27 | 27 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $144 → $149 | Hold | Maintains | $144 → $149 | +2.54% | Oct 10, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $190 | Strong Buy | Initiates | $190 | +30.75% | Sep 25, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 24, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 4, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $115 → $118 | Hold | Maintains | $115 → $118 | -18.79% | Aug 14, 2025 |
Financial Forecast
Revenue This Year
9.87B
from 9.68B
Increased by 2.00%
Revenue Next Year
9.48B
from 9.87B
Decreased by -3.94%
EPS This Year
16.19
from 11.18
Increased by 44.79%
EPS Next Year
16.13
from 16.19
Decreased by -0.37%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5B | 10.2B | |||
| Avg | 9.9B | 9.5B | |||
| Low | 9.3B | 8.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.8% | 3.6% | |||
| Avg | 2.0% | -3.9% | |||
| Low | -3.6% | -16.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.99 | 18.70 | |||
| Avg | 16.19 | 16.13 | |||
| Low | 15.20 | 13.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52.0% | 15.5% | |||
| Avg | 44.8% | -0.4% | |||
| Low | 36.0% | -15.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.